Navigation Links
GPhA Announces 2008-2009 Executive Committee; Teva North America's Bill Marth Elected as Chairman of the Board
Date:2/12/2008

BOCA RATON, Fla., Feb. 12 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) Board of Directors today named the members of its newly elected Executive Committee and announced the election of William Marth, President and CEO of Teva North America, to serve as its Chairman for 2008- 2009.

Mr. Marth has 30 years of experience in the pharmaceutical industry, including nearly a decade with Teva, which is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. Mr. Marth has served on GPhA's Board of Directors since 2005, most recently as Vice Chair.

"We are very pleased to welcome Bill as GPhA's Chairman of the Board," said Kathleen Jaeger, GPhA President and CEO. "2008 will be an extremely busy year and we look forward to Bill's excellent leadership as we work to increase consumer access to safe, affordable generic medicines.

"We also would like to extend our heartfelt thanks to Bruce Downey for his two years of outstanding service as chairman and for his dedication to the industry."

The GPhA Board also elected Hal Korman, President, North America, Mylan Inc., as its Vice Chairman and re-elected Rosendo Ferran, Senior Consultant, New Chemic, Inc., to serve as its Secretary-Treasurer. Bernhard Hampl, President and CEO, Sandoz US, and Bruce Downey, Chairman and CEO, Barr Pharmaceuticals Inc., will serve as at-large members on the Board's Executive Committee.

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Unbranded and branded generics represent 65% of the total prescriptions dispensed in the United States, but only 20% of all dollars spent on prescription drugs. For more information about the industry, visit http://www.gphaonline.org.
'/>"/>

SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:eDiets.com(R) Announces Q3 2008 Results 2Health News:eDiets.com(R) Announces Q3 2008 Results 3Health News:eDiets.com(R) Announces Q3 2008 Results 4Health News:eDiets.com(R) Announces Q3 2008 Results 5Health News:eDiets.com(R) Announces Q3 2008 Results 6Health News:eDiets.com(R) Announces Q3 2008 Results 7Health News:Pelvic Inflammation Puts Girls at Risk for Repeat STIs 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 3Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 2Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 3Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 5Health News:Leading Scientists From Around the World Headed to Kansas for Symposium on Combating Deadly Infectious Diseases 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 4
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Preventing toxic shock syndrome and other severe diseases 53247 1Got zinc 3F New zinc research suggests novel therapeutic targets 9433 1Got zinc 3F New zinc research suggests novel therapeutic targets 9433 2Recovery act funded research projects aid communities across the country 9428 1